Opus Genetics, Inc. (IRD) financial statements and ratios from SEC XBRL: revenue $14.20M (TTM), net margin -349.3%, revenue growth 29.1% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $14.20M |
| Net Margin | -349.3% |
| Revenue Growth (YoY) | 29.1% |
| EPS Growth (YoY) | -62.8% |
| Price / Sales | 41.25 |
| Altman Z-Score | -1.56 (distress) |
| Sector P/E (Healthcare) | 21.7 |
IRD overview · IRD earnings · IRD KPIs · IRD investor relations · IRD ownership · IRD peers · IRD filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.